Pharma BD Deal Intelligence
A $0.4B bolt-on protein-engineering platform quietly became the R&D engine behind Taltz, a $3.2B/year blockbuster. Lilly's 2003 acquisition of Applied Molecular Evolution seeded its San Diego biotech center, whose scientists engineered ixekizumab—one of Lilly's best-aged small deals.
A $0.4B bolt-on protein-engineering platform quietly became the R&D engine behind Taltz, a $3.2B/year blockbuster — one of Lilly's best-aged small deals.
Full analysis, sources & comparables →Lilly to acquire AME at $18/share in cash, stock, or combination; AMEsystem directed-evolution platform positioned as core to Lilly's biotechnology product…
Top 6 monoclonal antibodies grew at ~20% CAGR from 2004-2013, validating Lilly's 2003 strategic move to acquire antibody optimization capability via AME.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Announced November 21, 2003. $18/share = ~$400M. Antibody optimization platform (AMEsystem). Closed February 2004. Sources: SEC 425, Lilly investor PR, Pharmaletter.
A $0.4B bolt-on protein-engineering platform quietly became the R&D engine behind Taltz, a $3.2B/year blockbuster — one of Lilly's best-aged small deals.
Assessment window: 15yr post-close.
This was a platform/technology acquisition rather than a single-disease deal. Applied Molecular Evolution's AMEsystem applied directed molecular evolution to optimize antibody affinity, specificity, and developability — a horizontal capability spanning oncology, autoimmune, and inflammatory indications across Lilly's pipeline.
By 2003, the monoclonal antibody class was emerging as the dominant biologics modality — Remicade (J&J/Centocor), Rituxan (Genentech/Idec), Herceptin (Genentech), and Humira (Abbott, approved Dec 2002) were demonstrating that mAbs could anchor blockbuster franchises. Lilly, historically a small-molecule-led company strong in diabetes (Humalog), oncology (Gemzar), and CNS, was structurally underweight in biologics and lacked a proprietary antibody optimization engine — a gap competitors closed via Cambridge Antibody Technology (later AstraZeneca/MedImmune), Abgenix/Medarex (transgenic mice), and Genentech's internal capabilities. The $400M AME deal — at $18/share, 80% stock / 20% cash, closed February 2004 — gave Lilly the AMEsystem directed-evolution platform, AME's San Diego biologics site, and ~100 staff. The transaction's enduring value was infrastructure, not a single asset: the San Diego site became Lilly Biotechnology Center (San Diego), and AME-derived antibody engineering supported subsequent pipeline programs and partnerships, with Lilly later layering ImClone (2008, $6.5B) on top to fully build out its biologics franchise.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Applied Molecular Evolution Inc. (this deal) | 2003 | $400M | 88 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
| Eli Lilly and Company / Hanmi Pharmaceutical Co. Ltd. | 2026 | $1.3B | 65 |